Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Saliva Diagnostics (SALV) -- Ignore unavailable to you. Want to Upgrade?

To: rl who wrote (3351)	3/23/2000 9:48:00 AM
From: Shadow	Read Replies (1) \| Respond to of 3369

We used to get a $1 spike out of a PR like this. (COMTEX) B: SDS Announces the Approval of the First Point of Care Dev B: SDS Announces the Approval of the First Point of Care Device For HIV In Canada NEW YORK, Mar 23, 2000 (BUSINESS WIRE) -- Saliva Diagnostic Systems, Inc. (OTC BB:SALV); SDS announced today that its whole blood HIV-1 1/42 test (HemaStrip-HIV 1 1/42) has been approved and licensed for sale in Canada. The license has been issued to BioChem ImmunoSystems, SDS's marketing and development associate in Canada. To be marketed in Canada as the "Fast Check HIV1 1/42" (Whole Blood), it is the first licensed point of care device for the diagnosis of Human Immunodeficiency Viruses Type 1 and 2 ("HIV-1 and HIV-2"). Approval was granted after completion of one of the most extensive clinical studies ever performed in Canada. HemaStrip HIV1 1/42 is an in vitro point of care rapid test for the detection of IgG antibodies to HIV-1 and HIV-2 in whole blood. In Canada the device is approved for patient testing by health care professionals and is to be used only in sites where appropriate HIV counseling by a health care professional is available. "The Company believes this further validates the Company's patented and leading technology" stated Leo Ehrlich, President and CEO of SDS. "This is one of the most important developments in the history of SDS. It's a proud day for our stockholders. Canadian approval will help open additional new markets for the sale of SDS products. SDS is also excited about strengthening its relationship with BioChem ImmunoSystems. There are many other products that with joint collaboration can yield great results for both companies." The Company expects to begin shipments during the second quarter. The Company has recently relocated its administrative offices to 419 Park Ave. South, New York City (212-576-1501). For more information on SALV, please visit the Company's Web site at www.salv.com FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.